Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α

키워드

참고문헌 (98)

1. 송은미, "Natural history of inflammatory bowel disease: a comparison between the East and the West", Intestinal research, 20(4), pp.418~430 (2022), 대한장연구학회[DOI]
2. Bryant RV, "Conventional drug therapy for inflammatory bowel disease", Scand J Gastroenterol, 50, pp.90~112 (2015)
3. 박지혜, "Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management", The Korean Journal of Internal Medicine, 36(5), pp.1040~1048 (2021), 대한내과학회[DOI]
4. 윤준식, "Quality of information on the Internet for Korean patients with inflammatory bowel disease", The Korean Journal of Internal Medicine, 34(6), pp.1215~1222 (2019), 대한내과학회[DOI]
5. Turner D, "STRIDE-II : an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)Initiative of the International Organization for the Study of IBD(IOIBD) : determining therapeutic goals for treat-to-target strategies in IBD", Gastroenterology, 160, pp.1570~1583 (2021)
6. Jong Pil Im, "Changing treatment paradigms for the management of inflammatory bowel disease", The Korean Journal of Internal Medicine, 33(1), pp.28~35 (2018), 대한내과학회[DOI]
7. Ajit Sood, "Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease", Intestinal research, 18(4), pp.355~378 (2020), 대한장연구학회[DOI]
8. Plosker GL, "Sulfasalazine : a review of its use in the management of rheumatoid arthritis", Drugs, 65, pp.1825~1849 (2005)
9. Di Paolo MC, "Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis : report on tolerance and side-effects", Dig Liver Dis, 33, pp.563~569 (2001)
10. Mansfield JC, "A double-blind comparison of balsalazide, 6. 75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis", Aliment Pharmacol Ther, 16, pp.69~77 (2002)
11. Nielsen OH, "Drug insight : aminosalicylates for the treatment of IBD", Nat Clin Pract Gastroenterol Hepatol, 4, pp.160~170 (2007)
12. Berends SE, "Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis", Clin Pharmacokinet, 58, pp.15~37 (2019)
13. Yosuke Shimodaira, "Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan", Intestinal research, 19(2), pp.225~231 (2021), 대한장연구학회[DOI]
14. Thakral S, "Eudragit : a technology evaluation", Expert Opin Drug Deliv, 10, pp.131~149 (2013)
15. Varum F, "OPTICORE™, an innovative and accurate colonic targeting technology", Int J Pharm, 583, pp.119372~ (2020)
16. Nardelli S, "MMX®technology and its applications in gastrointestinal diseases", Therap Adv Gastroenterol, 10, pp.545~552 (2017)
17. Sonu I, "Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease", Gastroenterol Clin North Am, 39, pp.559~599 (2010)
18. Tamura S, "Mesalazine granule formulation improves clinical data in Crohn’s disease compared with tablet formulation", Sci Rep, 10, pp.21353~ (2020)
19. Veloso PM, "Mesalazine and inflammatory bowel disease : from well-established therapies to progress beyond the state of the art", Eur J Pharm Biopharm, 167, pp.89~103 (2021)
20. Peskar BM, "Possible mode of action of 5-aminosalicylic acid", Dig Dis Sci, 32(12 Suppl), pp.51~ (1987)[DOI]
21. Wahl C, "Sulfasalazine : a potent and specific inhibitor of nuclear factor kappa B", J Clin Invest, 101, pp.1163~1174 (1998)
22. Rousseaux C, "Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma", J Exp Med, 201, pp.1205~1215 (2005)
23. Couto D, "Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine", Redox Rep, 15, pp.259~267 (2010)
24. Lamb CA, "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults", Gut, 68(Suppl 3), pp.s1~s106 (2019)
25. Rubin DT, "ACG clinical guideline : ulcerative colitis in adults", Am J Gastroenterol, 114, pp.384~413 (2019)
26. 최창환, "궤양성 대장염 치료 가이드라인 개정판", 대한소화기학회지, 69(1), pp.1~28 (2017), 대한소화기학회[DOI]
27. Sandborn WJ, "Delayed-release oral mesalamine 4. 8 g", day(800-mg tablet)is effective for patients with moderately active ulcerative colitis, 2009, pp.137, 1934~1943
28. Lichtenstein GR, "Randomised clinical trial : delayed-release oral mesalazine 4. 8 g", day vs. 2. 4 g, Aliment Pharmacol Ther, pp.2011, 33[DOI]
29. Orchard TR, "Randomised clinical trial : early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis : new light on a familiar question", Aliment Pharmacol Ther, 33, pp.1028~1035 (2011)
30. Ford AC, "Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis : systematic review and meta-analysis", Am J Gastroenterol, 107, pp.167~176 (2012)
31. Osterman MT, "Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis", Clin Gastroenterol Hepatol, 12, pp.1887~1893 (2014)
32. d’Albasio G, "Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis : a randomized double-blind study", Am J Gastroenterol, 92, pp.1143~1147 (1997)
33. Feagan BG, "Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis", Cochrane Database Syst Rev, 10, pp.CD000543~ (2012)
34. Feagan BG, "Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis : a systematic review and meta-analysis", Inflamm Bowel Dis, 18, pp.1785~1794 (2012)
35. Kruis W, "Once daily versus three times daily mesalazine granules in active ulcerative colitis : a double-blind, double-dummy, randomised, non-inferiority trial", Gut, 58, pp.233~240 (2009)
36. Tripathi K, "Patient preference and adherence to aminosalicylates for the treatment of ulcerative colitis", Clin Exp Gastroenterol, 14, pp.343~351 (2021)
37. Shinta Mizuno, "5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis", Intestinal research, 18(1), pp.69~78 (2020), 대한장연구학회
38. Lim WC, "Aminosalicylates for induction of remission or response in Crohn’s disease", Cochrane Database Syst Rev, 7, pp.CD008870~ (2016)
39. Akobeng AK, "Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease", Cochrane Database Syst Rev, 9, pp.CD003715~ (2016)
40. Honap S, "5-ASAs in Crohn’s disease : time to stop the salicylate?", Dig Dis Sci, 67, pp.2699~2700 (2022)
41. Coward S, "Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease : a Bayesian network meta-analysis : republished", Inflamm Bowel Dis, 23, pp.E26~E37 (2017)
42. Bernstein CN, "Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD : a population-based study", Aliment Pharmacol Ther, 54, pp.814~832 (2021)
43. Xie C, "The culprit of mesalamine intolerance : case series and literature review", BMC Gastroenterol, 19, pp.138~ (2019)
44. Tsujii Y, "Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid : a single-center, observational study", Scand J Gastroenterol, 57, pp.190~196 (2022)
45. Wild GE, "The mechanisms of prednisone inhibition of inflammation in Crohn’s disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression", Aliment Pharmacol Ther, 18, pp.309~317 (2003)
46. Baron JH, "Out-patient treatment of ulcerative colitis : comparison between three doses of oral prednisone", Br Med J, 2, pp.441~443 (1962)
47. Waljee AK, "Corticosteroid use and complications in a US inflammatory bowel disease cohort", PLoS One, 11, pp.e0158017~ (2016)
48. Buchman AL, "Side effects of corticosteroid therapy", J Clin Gastroenterol, 33, pp.289~294 (2001)
49. Maconi G, "Budesonide MMX in the treatment of ulcerative colitis : current perspectives on efficacy and safety", Ther Clin Risk Manag, 17, pp.285~292 (2021)
50. Toshifumi Hibi, "Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials", Intestinal research, 18(1), pp.56~68 (2020), 대한장연구학회
51. Van Assche G, "Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis : results from a double-blind, randomized, parallel group study", Am J Gastroenterol, 110, pp.708~715 (2015)
52. 이윤지, "Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis", Yonsei Medical Journal, 58(1), pp.144~149 (2017), 연세대학교의과대학[DOI]
53. Lie MR, "No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative proctitis", Clin Gastroenterol Hepatol, 18, pp.1777~1784 (2020)
54. Caron B, "Efficacy of pharmacological agents for ulcerative proctitis : a systematic literature review", J Crohns Colitis, 16, pp.922~930 (2022)
55. Nunes T, "Oral locally active steroids in inflammatory bowel disease", J Crohns Colitis, 7, pp.183~191 (2013)
56. Laine L, "Considerations in the management of steroid-dependent Crohn’s disease", Gastroenterology, 125, pp.906~910 (2003)
57. Velayos F, "Management of steroid-dependent ulcerative colitis : immunomodulatory agents, biologics, or surgery?", Clin Gastroenterol Hepatol, 5, pp.668~671 (2007)
58. Arshdeep Singh, "Use of thiopurines in inflammatory bowel disease: an update", Intestinal research, 20(1), pp.11~30 (2022), 대한장연구학회[DOI]
59. Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease : a 30 year review", Gut, 50, pp.485~489 (2002)
60. Stournaras E, "Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease : long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource", Gut, 70, pp.677~686 (2021)
61. Xu Z, "Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy and safety", J Clin Pharmacol, 55(Suppl 3), pp.S60~S74 (2015)
62. Smith MA, "Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol", J Crohns Colitis, 6, pp.905~912 (2012)
63. Louis E, "Use of azathioprine in IBD : modern aspects of an old drug", Gut, 63, pp.1695~1699 (2014)
64. Gilissen LP, "Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy", J Crohns Colitis, 6, pp.698~707 (2012)
65. Crouwel F, "There is still a place for optimised thiopurine therapy in IBD", Gut, 70, pp.2207~ (2021)
66. Chaparro M, "Safety of thiopurine therapy in inflammatory bowel disease : long-term follow-up study of 3931 patients", Inflamm Bowel Dis, 19, pp.1404~1410 (2013)
67. Nagy F, "Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease", World J Gastroenterol, 14, pp.4342~4346 (2008)
68. Lees CW, "Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease", Aliment Pharmacol Ther, 27, pp.220~227 (2008)
69. Katsuyoshi Matsuoka, "NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease", Intestinal research, 18(3), pp.275~281 (2020), 대한장연구학회[DOI]
70. Chang JY, "Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 18, pp.2010~2018 (2020)
71. Derijks LJ, "Review article : thiopurines in inflammatory bowel disease", Aliment Pharmacol Ther, 24, pp.715~729 (2006)
72. Takato Maeda, "Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity", Intestinal research, 20(1), pp.90~100 (2022), 대한장연구학회[DOI]
73. Haisma SM, "Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines : a multicenter cohort study", J Crohns Colitis, 9, pp.305~311 (2015)
74. Huang Z, "Methotrexate for refractory Crohn’s disease compared with thiopurines : a retrospective non-head-to-head controlled study", Inflamm Bowel Dis, 23, pp.440~447 (2017)
75. Feuerstein JD, "AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis", Gastroenterology, 158, pp.1450~1461 (2020)
76. Feagan BG, "Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease", Gastroenterology, 146, pp.681~688 (2014)
77. Lichtenstein GR, "ACG clinical guideline : management of Crohn’s disease in adults", Am J Gastroenterol, 113, pp.481~517 (2018)
78. Vulliemoz M, "TNF-alpha blockers in inflammatory bowel diseases : practical recommendations and a user’s guide : an update", Digestion, 101(Suppl 1), pp.16~26 (2020)
79. Gecse K, "Fistulizing Crohn’s disease : diagnosis and management", United European Gastroenterol J, 1, pp.206~213 (2013)
80. Vaughn BP, "Prevention of post-operative recurrence of Crohn’s disease", World J Gastroenterol, 20, pp.1147~1154 (2014)
81. 오신주, "Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis", Intestinal research, 19(3), pp.323~331 (2021), 대한장연구학회[DOI]
82. Yoon Suk Jung, "Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study", The Korean Journal of Internal Medicine, 35(5), pp.1104~1113 (2020), 대한내과학회[DOI]
83. Schreiber S, "Randomized controlled trial : subcutaneous vs intravenous infliximab CTP13maintenance in inflammatory bowel disease", Gastroenterology, 160, pp.2340~2353 (2021)
84. Haruhiko Ogata, "Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study", Intestinal research, 19(4), pp.419~429 (2021), 대한장연구학회[DOI]
85. Tadakazu Hisamatsu, "Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study", Intestinal research, 19(4), pp.408~418 (2021), 대한장연구학회[DOI]
86. Yu Jongwook, "Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study", Gut and Liver, 16(5), pp.764~774 (2022), 거트앤리버 소화기연관학회협의회[DOI]
87. Murdaca G, "Infection risk associated with anti-TNF-α agents : a review", Expert Opin Drug Saf, 14, pp.571~582 (2015)
88. Saad Alrajhi, "Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease", Intestinal research, 18(3), pp.306~314 (2020), 대한장연구학회[DOI]
89. Hee Seung Hong, "Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases", The Korean Journal of Internal Medicine, 37(1), pp.73~84 (2022), 대한내과학회[DOI]
90. Annese V, "European Evidence-based Consensus : inflammatory bowel disease and malignancies", J Crohns Colitis, 9, pp.945~965 (2015)
91. Hiep Phan, "Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy", Intestinal research, 18(3), pp.282~288 (2020), 대한장연구학회[DOI]
92. Jacobstein DA, "Premedication and infusion reactions with infliximab : results from a pediatric inflammatory bowel disease consortium", Inflamm Bowel Dis, 11, pp.442~446 (2005)
93. Roda G, "Loss of response to anti-TNFs : definition, epidemiology, and management", Clin Transl Gastroenterol, 7, pp.e135~ (2016)
94. Seung Wook Hong, "Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease", The Korean Journal of Internal Medicine, 36, pp.9~17 (2021), 대한내과학회[DOI]
95. Wu Jia-Feng, "Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?", Gut and Liver, 16(4), pp.515~524 (2022), 거트앤리버 소화기연관학회협의회[DOI]
96. Papamichael K, "Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 17, pp.1655~1668 (2019)
97. Papamichael K, "Therapeutic drug monitoring in inflammatory bowel disease : for every patient and every drug?", Curr Opin Gastroenterol, 35, pp.302~310 (2019)
98. Argollo M, "Optimizing biologic therapy in IBD : how essential is therapeutic drug monitoring?", Nat Rev Gastroenterol Hepatol, 17, pp.702~710 (2020)

관련 논문AI추천